Literature DB >> 11508828

Serum anti-p53 autoantibodies in patients with type 1 diabetes.

E Di Cesare1, M Previti, F Lombardo, A Di Benedetto, N Mazzù, G Romano, F De Luca, A Lasco, D Cucinotta.   

Abstract

The presence of antibodies reacting with the p53 tumor suppressor protein has been described in patients with some autoimmune disorders. In this study we looked for serum anti-p53 antibodies in 64 patients with autoimmune type 1 diabetes mellitus within 4 mo of diagnosis. The presence of anti-p53 antibodies was observed in 6/64 (9.4%) subjects with type 1 diabetes, and in 1/44 (2.3%) subjects with other organ-specific autoimmune diseases (18 primary biliary cirrhosis, 10 autoimmune hepatitis, 16 thyroid diseases), but in none of 45 control subjects. No relationship was found between antibodies directed against islet- and non-islet-specific antigens and anti-p53 antibodies. These findings support a possible role for p53 in some autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508828

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  8 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases.

Authors:  Takashi Himoto; Hirohito Yoneyama; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Reiji Haba; Seishiro Watanabe; Shoichi Senda; Tsutomu Masaki
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

3.  Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.

Authors:  Yiwei Zhang; Shelya X Zeng; Qian Hao; Hua Lu
Journal:  Dev Biol       Date:  2017-01-22       Impact factor: 3.582

4.  Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

Authors:  R Chauhan; R Handa; T P Das; U Pati
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

5.  Regulation of GAD65 expression by SMAR1 and p53 upon Streptozotocin treatment.

Authors:  Sandeep Singh; Varsheish Raina; Pavithra Lakshminarsimhan Chavali; Taronish Dubash; Sreenath Kadreppa; Pradeep Parab; Samit Chattopadhyay
Journal:  BMC Mol Biol       Date:  2012-09-14       Impact factor: 2.946

6.  Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between Diabetes and Cancer.

Authors:  Rani Sauriasari; Andisyah Putri Sekar; Nurul Aisyah; Rezi Riadhi Syahdi; Eiji Matsuura
Journal:  Diabetes Metab Syndr Obes       Date:  2020-02-11       Impact factor: 3.168

7.  Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes.

Authors:  Bartosz Słomiński; Maria Skrzypkowska; Monika Ryba-Stanisławowska; Małgorzata Myśliwiec; Piotr Trzonkowski
Journal:  J Mol Med (Berl)       Date:  2021-01-25       Impact factor: 4.599

8.  Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma.

Authors:  Abdel Raouf Abou El Azm; Mohamed Yousef; Raafat Salah; Wael Mayah; Salwa Tawfeek; Hussien Ghorabah; Nagwa Mansour
Journal:  Springerplus       Date:  2013-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.